Recipharm completes two acquisitions

Published: 11-Apr-2022

Both CDMOs have established specialisms within the biologics space

Global CDMO Recipharm has announced the closing of its acquisitions of advanced therapy CDMO Arranta Bio and virotherapy CDMO Vibalogics.

The acquisitions are part of the company’s biologics strategy, which focuses particularly on drug substance manufacturing for advanced therapy medicinal products, or ATMPs. They follow the company’s entry into the market in early 2022 with the acquisition of Portuguese company GenIbet.

The acquisitions also enable a robust base in the US, the company says, with facilities in Boxborough, MA, and provide a platform from which to build its capabilities in new biologics modalities.

Both CDMOs have established specialisms within the biologics space. Boxborough-based Arranta has delivers microbiome therapeutic products and mRNA clinical production capabilities, while Vibalogics manufactures oncolytic viruses, viral vaccines and gene therapies, offering process and analytical development, manufacturing, testing and fill-finish services from facilities in Germany and America.

Marc Funk, CEO of Recipharm, said: “This acquisition is an important step in growing our biologics business and developing our US presence. We will be building on the pioneering excellence which lies at the heart of these companies and providing drug developers in the Biologics market with scientifically differentiated CDMO services and expertise for ATMPs.

“These deals, together with our recent acquisition of GenIbet, a specialist in the manufacture of biological clinical material, mean that we will be well placed to develop new capabilities in innovative technologies across gene therapy, viral vectors, mRNA/ plasmids, oncolytic virus and microbiome,” he said.

“We are thrilled to be closing both acquisitions and look forward to welcoming the Arranta Bio and Vibalogics teams into the Recipharm organisation.”

You may also like